Pancreatic Adenocarcinoma, Version 2.2017

Publication Type:

Journal Article

Authors:

Tempero, Margaret A; Malafa, Mokenge P; Al-Hawary, Mahmoud; Asbun, Horacio; Bain, Andrew; Behrman, Stephen W; Benson, Al B; Binder, Ellen; Cardin, Dana B.; Cha, Charles; Chiorean, E Gabriela; Chung, Vincent; Czito, Brian; Dillhoff, Mary; Dotan, Efrat; Ferrone, Cristina R.; Hardacre, Jeffrey; Hawkins, William G; Herman, Joseph; Ko, Andrew H; Komanduri, Srinadh; Koong, Albert; LoConte, Noelle; Lowy, Andrew M; Moravek, Cassadie; Nakakura, Eric K; O'Reilly, Eileen M; Obando, Jorge; Reddy, Sushanth; Scaife, Courtney; Thayer, Sarah; Weekes, Colin D; Wolff, Robert A; Wolpin, Brian M; Burns, Jennifer; Darlow, Susan

Source:

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, Volume 15, Issue 8, p.1028+ (2017)

Abstract:

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.